STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- CREATE Medicines rebranded from Myeloid Therapeutics last fall, retaining co‑founder Siddhartha Mukherjee, an oncologist and writer.
- CREATE Medicines focuses on CAR‑T therapies that employ myeloid cells to attack solid tumors and has added autoimmune disease programs to its pipeline.
- CREATE Medicines secured $122 million in new financing from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and other investors.
- CREATE Medicines will use the capital to advance its first CAR‑T candidates into human clinical trials.
Why it matters: Investors and patients stand to benefit as CREATE Medicines now has $122 M to push its first CAR‑T candidates into human trials, potentially accelerating treatments for solid tumors and autoimmune diseases.
